PF-06952229

PF-06952229 is a potent, selective, and orally bioavailable small-molecule inhibitor of transforming growth factor-beta receptor type 1 (TGFβR1/ALK5). It acts by specifically binding to TGFβR1 and preventing TGFβ-mediated signal transduction, thereby inhibiting phosphorylation of SMAD2 and dampening TGFβ signaling. This mechanism can reverse epithelial-mesenchymal transition (EMT), modulate the tumor immune microenvironment, and exert antitumor activity in preclinical models. Developed by Pfizer as an antineoplastic agent for advanced or metastatic solid tumors—including breast cancer, prostate cancer (mCRPC), head and neck squamous cell carcinoma, melanoma, mesothelioma, pancreatic cancer, colorectal cancer, renal cell carcinoma, and hepatocellular carcinoma—PF-06952229 reached phase 1 clinical trials but was discontinued for strategic reasons[1][2][3][4][5][6].